Ian Churchhill Anderson, MD
Hematology/Oncology · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 5
- Since medical school
- 38 years
- Duke University School of Medicine, 1988
Offices
5 locations · Providence Medical Foundation · 1,461 clinicians in this group
Hospitals listed: Adventist Health Mendocino Coast · Healdsburg Hospital · Petaluma Valley Hospital · Providence Santa Rosa Memorial Hospital · Sonoma Valley Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Anderson’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A49481 · Current
Licensed to practise in California · since 2000 · expires 2027-11-30 · Duke University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Mendocino CoastFort Bragg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 5 of 5 · 80% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- Healdsburg HospitalHealdsburg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Providence, which runs 54 hospitals in 7 states77% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Petaluma Valley HospitalPetaluma, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Adventist Health Mendocino Coast
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for heart failure patientsComplications and deaths | 9 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 103 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 268 cases | None | Jul 2024 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 78 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -24.2 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.7 · 102 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 101 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.7 (5.2 to 11.1) · 65 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.3 to 14.6) · 65 cases | No different | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.8 to 17.4) · 526 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 48 cases | No different | Jan 2024 – Dec 2024 |
What patients said (119 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 5 |
| Communication about medicines | 4 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 86% |
| Nurses "always" communicated well | 86% |
| Doctors "always" communicated well | 89% |
| Staff "always" explained | 72% |
| Yes, staff "did" give patients this information | 94% |
| Yes, staff "did" give patients information about help after discharge | 94% |
| Doctors "always" explained things so they could understand | 85% |
| Doctors "always" listened carefully | 87% |
| Doctors "always" treated them with courtesy and respect | 96% |
| Patients who gave a rating of "9" or "10" (high) | 86% |
| Staff "always" explained new medications | 87% |
| Nurses "always" explained things so they could understand | 82% |
| Nurses "always" listened carefully | 84% |
| Nurses "always" treated them with courtesy and respect | 92% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 57% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Healdsburg Hospital
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 1 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for pneumonia patientsComplications and deaths | 16.5 · 45 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 109 cases | None | Jul 2024 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.8 · 47 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 31 cases | None | Jul 2023 – Jun 2025 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 94% |
| Yes, staff "did" give patients information about help after discharge | 96% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 84% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 95% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Petaluma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.23 to 2.39) · 147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.44 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 57 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 533 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,427 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,398 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.65) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 202 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.61 (0 to 18.36) · 49 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.16 (0.85 to 9.47) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.41) · 1,184 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.1 · 26 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.308 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3 · 143 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 17.8) · 364 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 138 cases | No different | Jan 2024 – Dec 2024 |
What patients said (246 patients answered, 23% of those asked)
| Cleanliness | 5 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 85% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$195,376
Medicare paid this office $195,376 for 630 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 505 | $133,468 | $102 |
| Long return visit (40+ min) | 119 | $24,148 | $146 |
| New patient visit (60+ min) | 62 | $11,640 | $188 |
| New patient visit (45+ min) | 60 | $7,760 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,187 | $96 |
See all 8 services
| Return visit (30+ min) | 505 | $133,468 | $102 |
| Long return visit (40+ min) | 119 | $24,148 | $146 |
| New patient visit (60+ min) | 62 | $11,640 | $188 |
| New patient visit (45+ min) | 60 | $7,760 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,187 | $96 |
| Short return visit (20+ min) | 52 | $3,918 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,836 | $62 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 115 | $2,182 | $13 |
Who their Medicare patients are
630 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 15% · Women 61% · Also on Medicaid 16% · Health risk score 2.14. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 65% · Cancer 56% · Coronary heart disease 27% · Atrial fibrillation 25% · Chronic kidney disease 24% · Diabetes 23% · Depression 22% · Heart failure 20% · COPD 19% · Stroke 10% · Dementia 6%.
The office billed $827,538, Medicare allowed $263,400 and paid $195,376; for 1,963 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 630 | 1,963 | 76 | 2.14 | $827,538 | $195,376 |
| 2023 | 632 | 1,828 | 76 | 2.02 | $653,812 | $191,726 |
| 2022 | 610 | 2,063 | 76 | 1.98 | $713,049 | $224,415 |
| 2021 | 581 | 2,015 | 75 | 2.19 | $385,060 | $209,006 |
| 2020 | 572 | 1,929 | 75 | 2.26 | $369,360 | $169,676 |
| 2019 | 643 | 2,295 | 74 | 2.18 | $440,676 | $202,922 |
| 2018 | 651 | 1,989 | 75 | 2.30 | $372,053 | $167,345 |
| 2017 | 637 | 2,122 | 74 | 2.19 | $356,337 | $172,716 |
| 2016 | 591 | 2,112 | 75 | 2.04 | $343,977 | $167,550 |
| 2015 | 617 | 1,983 | 74 | 1.96 | $292,563 | $155,322 |
| 2014 | 878 | 43,010 | 74 | 1.95 | $1,729,272 | $617,359 |
| 2013 | 1,355 | 156,390 | 74 | 1.94 | $6,177,028 | $2,163,133 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 473 | $120,375 | $100 |
| Long return visit (40+ min) | 124 | $26,628 | $140 |
| New patient visit (60+ min) | 77 | $13,482 | $175 |
| New patient visit (45+ min) | 63 | $7,957 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $6,506 | $93 |
| Short return visit (20+ min) | 67 | $5,504 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $5,262 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $2,201 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,730 | $144 |
2022: 11 services
| Return visit (30+ min) | 436 | $122,398 | $108 |
| Long return visit (40+ min) | 138 | $34,524 | $156 |
| New patient visit (60+ min) | 80 | $15,102 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $9,018 | $60 |
| Telephone medical discussion with physician, 21-30 minutes | 67 | $8,369 | $105 |
| New patient visit (45+ min) | 62 | $8,149 | $131 |
| Short return visit (20+ min) | 80 | $7,882 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $7,411 | $87 |
| Telephone medical discussion with physician, 11-20 minutes | 63 | $5,820 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,195 | $169 |
| Telephone medical discussion with physician, 5-10 minutes | 37 | $2,025 | $48 |
2021: 10 services
| Return visit (30+ min) | 440 | $133,868 | $103 |
| Long return visit (40+ min) | 88 | $18,493 | $154 |
| Short return visit (20+ min) | 112 | $10,611 | $75 |
| New patient visit (60+ min) | 54 | $10,310 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $8,664 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $7,748 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,997 | $171 |
| New patient visit (45+ min) | 38 | $5,320 | $140 |
| Telephone medical discussion with physician, 21-30 minutes | 29 | $3,325 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 36 | $3,075 | $70 |
2020: 8 services
| Return visit (30+ min) | 448 | $114,202 | $86 |
| New patient visit (60+ min) | 64 | $10,524 | $164 |
| Long return visit (40+ min) | 67 | $9,310 | $121 |
| Short return visit (20+ min) | 113 | $9,008 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $8,968 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $6,202 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $5,391 | $174 |
| New patient visit (45+ min) | 35 | $4,550 | $130 |
2019: 9 services
| Return visit (30+ min) | 494 | $133,248 | $85 |
| New patient visit (60+ min) | 91 | $14,781 | $162 |
| Long return visit (40+ min) | 84 | $12,494 | $120 |
| Short return visit (20+ min) | 135 | $10,972 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $8,182 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $7,365 | $87 |
| New patient visit (45+ min) | 58 | $7,321 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $5,730 | $169 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $220 | $17 |
2018: 9 services
| Return visit (30+ min) | 472 | $101,494 | $80 |
| Long return visit (40+ min) | 97 | $13,419 | $109 |
| New patient visit (60+ min) | 74 | $12,119 | $164 |
| Short return visit (20+ min) | 141 | $10,127 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $6,608 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,503 | $163 |
| New patient visit (45+ min) | 49 | $6,414 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $6,152 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,078 | $109 |
2017: 10 services
| Return visit (30+ min) | 398 | $100,217 | $83 |
| Short return visit (20+ min) | 213 | $16,592 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $10,363 | $85 |
| New patient visit (60+ min) | 62 | $10,060 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $9,646 | $59 |
| Long return visit (40+ min) | 71 | $9,428 | $115 |
| New patient visit (45+ min) | 55 | $7,154 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,108 | $165 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,889 | $111 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $375 | $14 |
2016: 11 services
| Return visit (30+ min) | 376 | $92,883 | $83 |
| Short return visit (20+ min) | 273 | $21,408 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $11,687 | $57 |
| Long return visit (40+ min) | 76 | $11,044 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $8,587 | $83 |
| New patient visit (45+ min) | 61 | $7,399 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $5,145 | $161 |
| New patient visit (60+ min) | 31 | $5,087 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,194 | $109 |
| New patient visit (30+ min) | 12 | $1,039 | $87 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $228 | $15 |
2015: 11 services
| Return visit (30+ min) | 309 | $79,678 | $86 |
| Short return visit (20+ min) | 362 | $33,306 | $57 |
| New patient visit (45+ min) | 87 | $11,668 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $8,764 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $5,331 | $85 |
| Long return visit (40+ min) | 30 | $4,176 | $119 |
| New patient visit (60+ min) | 24 | $4,058 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,305 | $165 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,558 | $111 |
| New patient visit (30+ min) | 16 | $1,331 | $83 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $333 | $15 |
2014: 38 services
| Return visit (30+ min) | 294 | $73,028 | $85 |
| Injection, denosumab, 1 mg | 29 | $47,606 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $43,001 | None |
| Short return visit (20+ min) | 325 | $28,592 | $56 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 39 | $24,320 | None |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $11,168 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $7,443 | $58 |
| Injection, palonosetron hcl, 25 mcg | 26 | $7,039 | None |
| New patient visit (45+ min) | 46 | $6,059 | $132 |
| Long return visit (40+ min) | 39 | $5,640 | $118 |
| New patient visit (60+ min) | 34 | $5,457 | $161 |
| Blood test, comprehensive group of blood chemicals | 321 | $4,933 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $4,696 | $84 |
| Injection of additional new drug or substance into vein | 58 | $4,604 | $17 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 220 | $3,820 | $10 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $2,913 | $57 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $2,772 | $51 |
| New patient visit (30+ min) | 28 | $2,460 | $88 |
| Injection of drug or substance under skin or into muscle | 71 | $2,201 | $18 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,125 | $163 |
| Short return visit | 55 | $1,842 | $30 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,329 | $111 |
| Administration of chemotherapy into vein, each additional hour | 23 | $1,044 | $23 |
| Insertion of needle into vein for collection of blood sample | 196 | $930 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $905 | $36 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $720 | $24 |
| Lactate dehydrogenase (enzyme) level | 116 | $675 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $650 | $15 |
| Injection, paclitaxel, 30 mg | 11 | $539 | None |
| Injection, carboplatin, 50 mg | 14 | $475 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $427 | $24 |
| Blood test, basic group of blood chemicals (calcium, total) | 15 | $260 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $134 | None |
| Injection, granisetron hydrochloride, 100 mcg | 15 | $114 | None |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $54 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $24 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $23 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $6 | None |
2013: 69 services
| Injection, rituximab, 100 mg | 37 | $283,025 | None |
| Injection, denosumab, 1 mg | 56 | $215,955 | None |
| Injection, bevacizumab, 10 mg | 15 | $193,960 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 14 | $173,000 | None |
| Injection, pegfilgrastim, 6 mg | 43 | $153,627 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 73 | $87,129 | None |
| Injection, bortezomib, 0.1 mg | 12 | $70,360 | None |
| Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $64,969 | None |
| Administration of chemotherapy into vein, 1 hour or less | 158 | $61,887 | $119 |
| Return visit (30+ min) | 280 | $61,055 | $86 |
| Injection, fulvestrant, 25 mg | 11 | $58,720 | None |
| Short return visit (20+ min) | 358 | $34,036 | $58 |
| Injection, palonosetron hcl, 25 mcg | 79 | $31,429 | None |
| Blood test, comprehensive group of blood chemicals | 793 | $19,616 | $13 |
| Injection of additional new drug or substance into vein | 148 | $18,659 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $18,274 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 488 | $14,770 | $11 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 70 | $14,559 | $60 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 29 | $13,965 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $11,228 | $57 |
| Injection, zoledronic acid (zometa), 1 mg | 11 | $11,058 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 67 | $10,512 | $60 |
| Injection, fosaprepitant, 1 mg | 21 | $9,601 | None |
| Injection of drug or substance under skin or into muscle | 161 | $9,443 | $21 |
| New patient visit (60+ min) | 39 | $6,338 | $163 |
| Administration of chemotherapy into vein, each additional hour | 66 | $5,883 | $25 |
| New patient visit (45+ min) | 44 | $5,746 | $131 |
| Long return visit (40+ min) | 41 | $5,363 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $4,183 | $60 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 22 | $4,119 | None |
| Administration of additional new drug or substance into vein using push technique | 21 | $3,581 | $53 |
| Insertion of needle into vein for collection of blood sample | 427 | $3,297 | $3 |
| Administration of prolonged chemotherapy into vein | 12 | $3,245 | $120 |
| Short return visit | 75 | $2,933 | $35 |
| Carcinoembryonic antigen (cea) protein level | 79 | $2,823 | $26 |
| Injection of drug or substance into vein | 35 | $2,810 | $47 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $2,762 | $27 |
| Lactate dehydrogenase (enzyme) level | 305 | $2,588 | $5 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $2,386 | $26 |
| Injection, carboplatin, 50 mg | 44 | $2,366 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,228 | $159 |
| Injection, paclitaxel, 30 mg | 26 | $2,121 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 24 | $1,819 | $18 |
| Biopsy of bone marrow | 12 | $1,791 | $138 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,785 | $105 |
| New patient visit (30+ min) | 21 | $1,761 | $84 |
| Irrigation of implanted venous access drug delivery device | 33 | $1,130 | $21 |
| Blood creatinine level | 129 | $941 | $7 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 18 | $772 | $29 |
| Blood test, basic group of blood chemicals (calcium, total) | 55 | $769 | $11 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 21 | $724 | $28 |
| Psa (prostate specific antigen) measurement, total | 20 | $657 | $25 |
| Infusion into a vein for hydration, each additional hour | 21 | $652 | $12 |
| Injection, granisetron hydrochloride, 100 mcg | 50 | $593 | None |
| Collection of blood sample from implanted device | 25 | $587 | $18 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $559 | $17 |
| Injection, fluorouracil, 500 mg | 15 | $503 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 137 | $476 | None |
| Injection, etoposide, 10 mg | 12 | $474 | None |
| Magnesium level | 36 | $426 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $327 | $16 |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $146 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 12 | $131 | $10 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 25 | $125 | $5 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 11 | $102 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $84 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $31 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $29 | None |
| Injection, magnesium sulfate, per 500 mg | 11 | $22 | None |
Medicaid work
$13,069 in 2024
Medicaid paid $13,069 for 340 billed services this clinician did in 2024, up to 35 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 312 | $12,929 |
| Screening for depression is documented as negative, a follow-up plan is not required | 28 | $140 |
| 2024 | 340 | 2 | 35 | $13,069 |
| 2023 | 330 | 2 | 34 | $11,860 |
| 2022 | 210 | 1 | 34 | $9,300 |
| 2021 | 251 | 2 | 25 | $14,917 |
| 2020 | 175 | 1 | 30 | $12,198 |
| 2019 | 214 | 1 | 27 | $14,506 |
| 2018 | 213 | 1 | 25 | $14,692 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 301 | $11,715 |
| Screening for depression is documented as negative, a follow-up plan is not required | 29 | $145 |
2022
| Return visit (30+ min) | 210 | $9,300 |
2021
| Return visit (30+ min) | 228 | $13,739 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 23 | $1,178 |
2020
| Return visit (30+ min) | 175 | $12,198 |
2019
| Return visit (30+ min) | 214 | $14,506 |
2018
| Return visit (30+ min) | 213 | $14,692 |
Drugs they prescribed that Part D paid
$5,747,660
Pharmacies billed $5,747,660 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (152 of 2,030) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 11% of their opioid prescriptions.
1,557 generic and fewer than 11 brand-name prescriptions · $5,747,660 in drug cost · 31 antibiotic prescriptions to 22 people · 37 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 47 | $765,286 | $16,283 |
| Verzenio | 41 | $520,617 | $12,698 |
| Ibrance | 32 | $516,927 | $16,154 |
| Imbruvica | 38 | $511,250 | $13,454 |
| Alecensa | 26 | $482,565 | $18,560 |
See all 44 drugs
| Tagrisso | 47 | $765,286 | $16,283 |
| Verzenio | 41 | $520,617 | $12,698 |
| Ibrance | 32 | $516,927 | $16,154 |
| Imbruvica | 38 | $511,250 | $13,454 |
| Alecensa | 26 | $482,565 | $18,560 |
| Lenalidomide | 42 | $473,451 | $11,273 |
| Jakafi | 24 | $395,264 | $16,469 |
| Calquence | 23 | $343,365 | $14,929 |
| Revlimid | 14 | $224,221 | $16,016 |
| Abiraterone Acetate | 41 | $75,436 | $1,840 |
| Eliquis | 47 | $37,008 | $787 |
| Imatinib Mesylate | 18 | $26,379 | $1,466 |
| Xarelto | 22 | $17,933 | $815 |
| Letrozole | 167 | $5,024 | $30 |
| Exemestane | 37 | $4,091 | $111 |
| Potassium Chloride | 87 | $2,419 | $28 |
| Oxycodone | 54 | $1,394 | $26 |
| Tamoxifen Citrate | 87 | $1,323 | $15 |
| Ondansetron | 56 | $1,238 | $22 |
| Prochlorperazine Maleate | 90 | $927 | $10 |
| Dexamethasone | 91 | $887 | $10 |
| Hydrocodone-Acetaminophen | 32 | $669 | $21 |
| Anastrozole | 23 | $665 | $29 |
| Hydroxyurea | 38 | $643 | $17 |
| Ondansetron Odt | 29 | $610 | $21 |
| Gabapentin | 28 | $436 | $16 |
| Hydromorphone | 16 | $381 | $24 |
| Diphenoxylate-Atropine | 17 | $371 | $22 |
| Albuterol Sulfate Hfa | 15 | $334 | $22 |
| Hydrocortisone | 11 | $303 | $28 |
| Lorazepam | 62 | $294 | $5 |
| Olanzapine | 43 | $271 | $6 |
| Tamsulosin | 13 | $255 | $20 |
| Prednisone | 74 | $224 | $3 |
| Acyclovir | 24 | $222 | $9 |
| Klor-Con 10 | 20 | $207 | $10 |
| Pantoprazole | 16 | $207 | $13 |
| Omeprazole | 21 | $198 | $9 |
| Zolpidem | 29 | $150 | $5 |
| Levothyroxine | 24 | $136 | $6 |
| Tramadol | 17 | $128 | $8 |
| Famotidine | 14 | $99 | $7 |
| Citalopram Hbr | 14 | $74 | $5 |
| Lisinopril | 14 | $63 | $4 |
Year by year
| 2024 | 2,030 | 366 | 8% (152) | None | $5,747,660 |
| 2023 | 2,183 | 389 | 8% (181) | None | $5,825,409 |
| 2022 | 1,976 | 351 | 8% (161) | None | $7,001,416 |
| 2021 | 2,085 | 297 | 7% (144) | None | $6,599,359 |
| 2020 | 1,952 | 288 | 8% (157) | None | $5,374,034 |
| 2019 | 1,963 | 306 | 8% (161) | 30% | $4,281,070 |
| 2018 | 1,897 | 266 | 8% (148) | 25% | $3,128,642 |
| 2017 | 1,615 | 251 | 7% (112) | None | $2,630,959 |
| 2016 | 1,550 | 270 | 10% (161) | 18% | $1,783,632 |
| 2015 | 1,425 | 227 | 13% (187) | None | $1,214,697 |
| 2014 | 1,325 | 225 | 12% (161) | 18% | $1,097,767 |
| 2013 | 1,245 | 214 | 16% (198) | None | $1,030,091 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Revlimid | 35 | $670,370 | $19,153 |
| Jakafi | 25 | $452,847 | $18,114 |
| Ibrance | 29 | $437,302 | $15,079 |
| Lenalidomide | 32 | $432,085 | $13,503 |
| Imbruvica | 38 | $429,346 | $11,299 |
| Calquence | 25 | $380,497 | $15,220 |
| Alecensa | 18 | $333,171 | $18,510 |
| Tagrisso | 18 | $328,498 | $18,250 |
| Tasigna | 16 | $323,265 | $20,204 |
| Verzenio | 20 | $304,382 | $15,219 |
| Abiraterone Acetate | 50 | $219,911 | $4,398 |
| Lynparza | 15 | $176,334 | $11,756 |
| Gleevec | 11 | $125,002 | $11,364 |
| Eliquis | 66 | $47,555 | $721 |
| Imatinib Mesylate | 21 | $43,962 | $2,093 |
| Xarelto | 27 | $16,897 | $626 |
| Letrozole | 208 | $12,340 | $59 |
| Exemestane | 21 | $4,785 | $228 |
| Potassium Chloride | 87 | $2,091 | $24 |
| Hydrocodone-Acetaminophen | 56 | $1,864 | $33 |
| Prochlorperazine Maleate | 104 | $1,164 | $11 |
| Acyclovir | 74 | $1,123 | $15 |
| Anastrozole | 31 | $1,051 | $34 |
| Oxycodone | 35 | $1,045 | $30 |
| Tamoxifen Citrate | 58 | $1,006 | $17 |
| Hydroxyurea | 44 | $996 | $23 |
| Lorazepam | 95 | $886 | $9 |
| Ondansetron | 54 | $642 | $12 |
| Dexamethasone | 55 | $599 | $11 |
| Prednisone | 90 | $587 | $7 |
| Levothyroxine | 47 | $426 | $9 |
| Methadone | 16 | $424 | $26 |
| Ondansetron Odt | 29 | $409 | $14 |
| Mirtazapine | 14 | $398 | $28 |
| Diphenoxylate-Atropine | 21 | $390 | $19 |
| Gabapentin | 28 | $362 | $13 |
| Omeprazole | 15 | $325 | $22 |
| Albuterol Sulfate Hfa | 11 | $311 | $28 |
| Olanzapine | 38 | $298 | $8 |
| Nystatin | 11 | $262 | $24 |
| Klor-Con 10 | 22 | $259 | $12 |
| Tramadol | 40 | $257 | $6 |
| Warfarin | 12 | $96 | $8 |
| Citalopram Hbr | 26 | $94 | $4 |
| Diazepam | 15 | $62 | $4 |
| Zolpidem | 16 | $43 | $3 |
2022: 41 drugs
| Revlimid | 121 | $2,385,413 | $19,714 |
| Ibrance | 49 | $651,681 | $13,300 |
| Imbruvica | 52 | $592,345 | $11,391 |
| Jakafi | 30 | $449,361 | $14,979 |
| Tagrisso | 22 | $364,956 | $16,589 |
| Alecensa | 20 | $350,176 | $17,509 |
| Tepmetko | 11 | $244,052 | $22,187 |
| Abiraterone Acetate | 43 | $243,001 | $5,651 |
| Calquence | 18 | $235,318 | $13,073 |
| Deferasirox | 15 | $55,769 | $3,718 |
| Imatinib Mesylate | 13 | $48,679 | $3,745 |
| Eliquis | 56 | $44,796 | $800 |
| Xarelto | 39 | $28,023 | $719 |
| Letrozole | 140 | $6,059 | $43 |
| Exemestane | 17 | $4,447 | $262 |
| Oxycodone | 41 | $2,064 | $50 |
| Ondansetron | 51 | $1,291 | $25 |
| Acyclovir | 74 | $1,261 | $17 |
| Ondansetron Odt | 52 | $1,139 | $22 |
| Potassium Chloride | 68 | $1,058 | $16 |
| Hydroxyurea | 32 | $1,046 | $33 |
| Hydrocodone-Acetaminophen | 42 | $948 | $23 |
| Prochlorperazine Maleate | 80 | $908 | $11 |
| Tamoxifen Citrate | 27 | $755 | $28 |
| Morphine Sulfate Er | 16 | $733 | $46 |
| Gabapentin | 43 | $710 | $17 |
| Dexamethasone | 53 | $681 | $13 |
| Anastrozole | 25 | $567 | $23 |
| Lorazepam | 93 | $487 | $5 |
| Prednisone | 58 | $476 | $8 |
| Olanzapine | 16 | $417 | $26 |
| Omeprazole | 32 | $414 | $13 |
| Methadone | 16 | $285 | $18 |
| Levothyroxine | 19 | $189 | $10 |
| Zolpidem | 27 | $171 | $6 |
| Pantoprazole | 18 | $158 | $9 |
| Mirtazapine | 15 | $138 | $9 |
| Tramadol | 15 | $117 | $8 |
| Citalopram Hbr | 23 | $74 | $3 |
| Diazepam | 13 | $56 | $4 |
| Furosemide | 15 | $43 | $3 |
2021: 43 drugs
| Revlimid | 118 | $2,136,074 | $18,102 |
| Ibrance | 87 | $1,143,091 | $13,139 |
| Imbruvica | 72 | $843,088 | $11,710 |
| Tagrisso | 19 | $312,777 | $16,462 |
| Abiraterone Acetate | 53 | $261,313 | $4,930 |
| Alecensa | 13 | $214,828 | $16,525 |
| Lynparza | 13 | $192,731 | $14,825 |
| Creon | 17 | $47,135 | $2,773 |
| Eliquis | 64 | $39,464 | $617 |
| Xarelto | 26 | $19,574 | $753 |
| Exemestane | 28 | $8,790 | $314 |
| Imatinib Mesylate | 12 | $6,348 | $529 |
| Letrozole | 184 | $5,129 | $28 |
| Acyclovir | 108 | $2,159 | $20 |
| Hydroxyurea | 46 | $1,779 | $39 |
| Dexamethasone | 68 | $1,640 | $24 |
| Tamoxifen Citrate | 35 | $1,580 | $45 |
| Hydrocodone-Acetaminophen | 47 | $1,357 | $29 |
| Diphenoxylate-Atropine | 22 | $1,255 | $57 |
| Potassium Chloride | 49 | $1,153 | $24 |
| Oxycodone | 35 | $1,124 | $32 |
| Ondansetron | 65 | $1,122 | $17 |
| Prochlorperazine Maleate | 66 | $1,022 | $15 |
| Morphine Sulfate Er | 12 | $989 | $82 |
| Anastrozole | 37 | $969 | $26 |
| Ondansetron Odt | 45 | $722 | $16 |
| Gabapentin | 61 | $709 | $12 |
| Valacyclovir | 15 | $613 | $41 |
| Omeprazole | 65 | $612 | $9 |
| Oxycodone-Acetaminophen | 14 | $520 | $37 |
| Prednisone | 56 | $491 | $9 |
| Lorazepam | 64 | $452 | $7 |
| Levothyroxine | 36 | $417 | $12 |
| Levetiracetam | 12 | $306 | $26 |
| Acetaminophen-Codeine | 12 | $297 | $25 |
| Lidocaine-Prilocaine | 12 | $154 | $13 |
| Zolpidem | 22 | $146 | $7 |
| Lisinopril | 20 | $123 | $6 |
| Tramadol | 15 | $118 | $8 |
| Sulfamethoxazole-Trimethoprim | 18 | $96 | $5 |
| Diazepam | 11 | $52 | $5 |
| Warfarin | 13 | $50 | $4 |
| Furosemide | 11 | $50 | $5 |
2020: 46 drugs
| Revlimid | 104 | $1,780,436 | $17,120 |
| Ibrance | 65 | $909,980 | $14,000 |
| Imbruvica | 49 | $595,252 | $12,148 |
| Pomalyst | 15 | $305,069 | $20,338 |
| Afinitor | 11 | $194,875 | $17,716 |
| Tagrisso | 12 | $193,651 | $16,138 |
| Zytiga | 11 | $116,111 | $10,556 |
| Eliquis | 71 | $41,910 | $590 |
| Abiraterone Acetate | 13 | $26,468 | $2,036 |
| Xarelto | 24 | $20,830 | $868 |
| Fondaparinux | 12 | $15,956 | $1,330 |
| Exemestane | 24 | $7,140 | $297 |
| Letrozole | 230 | $5,994 | $26 |
| Tamoxifen Citrate | 53 | $3,007 | $57 |
| Acyclovir | 88 | $2,416 | $27 |
| Dexamethasone | 59 | $1,799 | $30 |
| Hydroxyurea | 43 | $1,720 | $40 |
| Oxycodone | 39 | $1,392 | $36 |
| Oxycodone-Acetaminophen | 26 | $1,284 | $49 |
| Valacyclovir | 19 | $1,148 | $60 |
| Potassium Chloride | 42 | $1,049 | $25 |
| Methylprednisolone | 13 | $1,027 | $79 |
| Morphine Sulfate Er | 11 | $971 | $88 |
| Ondansetron Odt | 43 | $876 | $20 |
| Anastrozole | 33 | $834 | $25 |
| Prochlorperazine Maleate | 56 | $783 | $14 |
| Hydrocodone-Acetaminophen | 36 | $730 | $20 |
| Omeprazole | 40 | $683 | $17 |
| Prednisone | 70 | $612 | $9 |
| Diphenoxylate-Atropine | 22 | $606 | $28 |
| Pregabalin | 12 | $605 | $50 |
| Ondansetron | 40 | $598 | $15 |
| Levothyroxine | 32 | $450 | $14 |
| Lorazepam | 71 | $417 | $6 |
| Tramadol | 12 | $349 | $29 |
| Klor-Con 10 | 13 | $322 | $25 |
| Gabapentin | 26 | $208 | $8 |
| Lidocaine-Prilocaine | 11 | $189 | $17 |
| Warfarin | 18 | $185 | $10 |
| Citalopram Hbr | 26 | $182 | $7 |
| Acetaminophen-Codeine | 11 | $155 | $14 |
| Zolpidem | 14 | $151 | $11 |
| Alendronate | 14 | $119 | $9 |
| Furosemide | 24 | $95 | $4 |
| Lisinopril | 18 | $74 | $4 |
| Sulfamethoxazole-Trimethoprim | 12 | $39 | $3 |
2019: 46 drugs
| Revlimid | 73 | $1,167,277 | $15,990 |
| Ibrance | 51 | $632,789 | $12,408 |
| Zytiga | 44 | $486,011 | $11,046 |
| Imbruvica | 39 | $419,580 | $10,758 |
| Tagrisso | 15 | $225,643 | $15,043 |
| Afinitor | 11 | $182,123 | $16,557 |
| Ninlaro | 15 | $155,797 | $10,386 |
| Abiraterone Acetate | 25 | $131,409 | $5,256 |
| Eliquis | 102 | $54,082 | $530 |
| Creon | 14 | $36,234 | $2,588 |
| Fondaparinux | 13 | $30,148 | $2,319 |
| Xarelto | 34 | $21,519 | $633 |
| Letrozole | 241 | $6,312 | $26 |
| Exemestane | 13 | $5,181 | $399 |
| Tamoxifen Citrate | 62 | $2,732 | $44 |
| Oxycodone | 33 | $1,742 | $53 |
| Hydrocodone-Acetaminophen | 42 | $1,550 | $37 |
| Potassium Chloride | 55 | $1,311 | $24 |
| Hydroxyurea | 48 | $1,116 | $23 |
| Acyclovir | 68 | $1,063 | $16 |
| Methylprednisolone | 14 | $1,049 | $75 |
| Anastrozole | 37 | $979 | $26 |
| Dexamethasone | 49 | $884 | $18 |
| Oxycodone-Acetaminophen | 20 | $816 | $41 |
| Morphine Sulfate Er | 14 | $797 | $57 |
| Prednisone | 76 | $769 | $10 |
| Ondansetron Odt | 33 | $753 | $23 |
| Levothyroxine | 30 | $484 | $16 |
| Mirtazapine | 22 | $483 | $22 |
| Prochlorperazine Maleate | 47 | $436 | $9 |
| Lorazepam | 78 | $403 | $5 |
| Gabapentin | 26 | $366 | $14 |
| Diphenoxylate-Atropine | 13 | $337 | $26 |
| Ondansetron | 29 | $335 | $12 |
| Ranitidine | 13 | $262 | $20 |
| Valacyclovir | 11 | $230 | $21 |
| Omeprazole | 29 | $219 | $8 |
| Sumatriptan | 12 | $187 | $16 |
| Venlafaxine Hcl Er | 11 | $177 | $16 |
| Zolpidem | 21 | $159 | $8 |
| Tramadol | 18 | $112 | $6 |
| Citalopram Hbr | 31 | $86 | $3 |
| Tamsulosin | 19 | $80 | $4 |
| Sulfamethoxazole-Trimethoprim | 14 | $77 | $5 |
| Furosemide | 19 | $46 | $2 |
| Lisinopril | 11 | $44 | $4 |
2018: 46 drugs
| Revlimid | 44 | $707,540 | $16,080 |
| Zytiga | 42 | $432,763 | $10,304 |
| Ibrance | 29 | $344,633 | $11,884 |
| Gleevec | 22 | $223,971 | $10,181 |
| Alecensa | 11 | $172,423 | $15,675 |
| Verzenio | 15 | $166,584 | $11,106 |
| Imbruvica | 14 | $150,805 | $10,772 |
| Xtandi | 14 | $116,432 | $8,317 |
| Eliquis | 81 | $41,496 | $512 |
| Creon | 14 | $40,618 | $2,901 |
| Xarelto | 31 | $14,919 | $481 |
| Letrozole | 295 | $5,765 | $20 |
| Tamoxifen Citrate | 86 | $2,778 | $32 |
| Ondansetron Odt | 50 | $1,500 | $30 |
| Hydrocodone-Acetaminophen | 46 | $1,327 | $29 |
| Oxycodone | 28 | $1,257 | $45 |
| Methylprednisolone | 12 | $1,062 | $89 |
| Anastrozole | 40 | $935 | $23 |
| Oxycodone-Acetaminophen | 15 | $835 | $56 |
| Hydroxyurea | 38 | $737 | $19 |
| Klor-Con 10 | 12 | $652 | $54 |
| Morphine Sulfate | 15 | $644 | $43 |
| Potassium Chloride | 27 | $613 | $23 |
| Acyclovir | 45 | $613 | $14 |
| Lorazepam | 111 | $582 | $5 |
| Diphenoxylate-Atropine | 13 | $544 | $42 |
| Prednisone | 57 | $494 | $9 |
| Prochlorperazine Maleate | 63 | $482 | $8 |
| Omeprazole | 54 | $469 | $9 |
| Levothyroxine | 40 | $428 | $11 |
| Methadone | 13 | $395 | $30 |
| Dexamethasone | 28 | $386 | $14 |
| Ondansetron | 29 | $310 | $11 |
| Lidocaine-Prilocaine | 17 | $293 | $17 |
| Valacyclovir | 12 | $289 | $24 |
| Tamsulosin | 20 | $257 | $13 |
| Zolpidem | 30 | $241 | $8 |
| Temazepam | 25 | $212 | $8 |
| Gabapentin | 17 | $196 | $12 |
| Mirtazapine | 11 | $196 | $18 |
| Sumatriptan | 13 | $157 | $12 |
| Trazodone | 12 | $153 | $13 |
| Tramadol | 11 | $127 | $12 |
| Ibuprofen | 11 | $64 | $6 |
| Citalopram Hbr | 11 | $54 | $5 |
| Lisinopril | 19 | $49 | $3 |
2017: 38 drugs
| Revlimid | 50 | $660,884 | $13,218 |
| Zytiga | 32 | $289,035 | $9,032 |
| Imbruvica | 26 | $254,369 | $9,783 |
| Ibrance | 20 | $226,083 | $11,304 |
| Pomalyst | 15 | $223,863 | $14,924 |
| Gleevec | 19 | $194,410 | $10,232 |
| Afinitor | 12 | $161,300 | $13,442 |
| Alecensa | 11 | $158,188 | $14,381 |
| Eliquis | 42 | $17,563 | $418 |
| Xarelto | 21 | $9,659 | $460 |
| Exemestane | 19 | $5,526 | $291 |
| Letrozole | 255 | $5,361 | $21 |
| Tamoxifen Citrate | 64 | $1,963 | $31 |
| Anastrozole | 37 | $775 | $21 |
| Hydroxyurea | 38 | $763 | $20 |
| Acyclovir | 53 | $727 | $14 |
| Ondansetron Odt | 41 | $678 | $17 |
| Morphine Sulfate Er | 14 | $650 | $46 |
| Hydrocodone-Acetaminophen | 29 | $543 | $19 |
| Levothyroxine | 41 | $510 | $12 |
| Prednisone | 69 | $501 | $7 |
| Omeprazole | 53 | $458 | $9 |
| Dexamethasone | 29 | $451 | $16 |
| Morphine Sulfate | 17 | $438 | $26 |
| Oxycodone | 11 | $410 | $37 |
| Nystatin | 11 | $396 | $36 |
| Lorazepam | 77 | $392 | $5 |
| Gabapentin | 16 | $366 | $23 |
| Zolpidem | 43 | $314 | $7 |
| Prochlorperazine Maleate | 54 | $287 | $5 |
| Lidocaine-Prilocaine | 11 | $275 | $25 |
| Ondansetron | 25 | $262 | $10 |
| Valacyclovir | 11 | $243 | $22 |
| Klor-Con Sprinkle | 13 | $217 | $17 |
| Spironolactone | 12 | $135 | $11 |
| Alendronate | 12 | $127 | $11 |
| Pantoprazole | 13 | $106 | $8 |
| Citalopram Hbr | 12 | $54 | $4 |
2016: 41 drugs
| Gleevec | 22 | $224,553 | $10,207 |
| Xalkori | 15 | $222,234 | $14,816 |
| Revlimid | 19 | $219,192 | $11,536 |
| Pomalyst | 11 | $148,755 | $13,523 |
| Ibrance | 14 | $146,403 | $10,457 |
| Xtandi | 15 | $123,859 | $8,257 |
| Imbruvica | 11 | $107,794 | $9,799 |
| Zytiga | 12 | $99,377 | $8,281 |
| Xarelto | 19 | $6,751 | $355 |
| Letrozole | 209 | $4,068 | $19 |
| Exemestane | 19 | $3,852 | $203 |
| Enoxaparin | 11 | $3,686 | $335 |
| Hydrocodone-Acetaminophen | 56 | $1,969 | $35 |
| Tamoxifen Citrate | 57 | $1,385 | $24 |
| Fentanyl | 15 | $1,317 | $88 |
| Oxycodone | 30 | $1,275 | $42 |
| Lorazepam | 90 | $706 | $8 |
| Ondansetron Odt | 46 | $584 | $13 |
| Anastrozole | 31 | $532 | $17 |
| Prochlorperazine Maleate | 74 | $505 | $7 |
| Hydroxyurea | 29 | $501 | $17 |
| Morphine Sulfate | 15 | $491 | $33 |
| Dexamethasone | 33 | $426 | $13 |
| Omeprazole | 60 | $414 | $7 |
| Gabapentin | 24 | $399 | $17 |
| Zolpidem | 43 | $378 | $9 |
| Lidocaine-Prilocaine | 11 | $334 | $30 |
| Nystatin | 12 | $302 | $25 |
| Acyclovir | 17 | $285 | $17 |
| Prednisone | 28 | $241 | $9 |
| Pravastatin | 12 | $236 | $20 |
| Potassium Chloride | 14 | $226 | $16 |
| Levothyroxine | 18 | $203 | $11 |
| Bicalutamide | 11 | $162 | $15 |
| Ondansetron | 20 | $141 | $7 |
| Naproxen | 12 | $109 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $87 | $5 |
| Alprazolam | 12 | $51 | $4 |
| Hydrochlorothiazide | 17 | $47 | $3 |
| Fluoxetine | 11 | $33 | $3 |
| Amlodipine Besylate | 13 | $23 | $2 |
2015: 34 drugs
| Revlimid | 27 | $294,758 | $10,917 |
| Gleevec | 19 | $185,875 | $9,783 |
| Xalkori | 11 | $152,525 | $13,866 |
| Xtandi | 13 | $111,205 | $8,554 |
| Imbruvica | 11 | $99,789 | $9,072 |
| Tarceva | 13 | $77,660 | $5,974 |
| Exemestane | 27 | $6,833 | $253 |
| Xarelto | 11 | $5,539 | $504 |
| Letrozole | 238 | $3,321 | $14 |
| Oxycontin | 11 | $2,359 | $214 |
| Oxycodone | 39 | $1,609 | $41 |
| Hydrocodone-Acetaminophen | 61 | $1,538 | $25 |
| Tamoxifen Citrate | 38 | $1,185 | $31 |
| Anastrozole | 88 | $969 | $11 |
| Lorazepam | 110 | $900 | $8 |
| Morphine Sulfate Er | 16 | $880 | $55 |
| Ondansetron Odt | 31 | $728 | $23 |
| Omeprazole | 74 | $508 | $7 |
| Hydroxyurea | 34 | $418 | $12 |
| Dexamethasone | 34 | $361 | $11 |
| Zolpidem | 21 | $357 | $17 |
| Gabapentin | 24 | $340 | $14 |
| Prochlorperazine Maleate | 48 | $260 | $5 |
| Tamsulosin | 11 | $251 | $23 |
| Prednisone | 30 | $243 | $8 |
| Bicalutamide | 16 | $224 | $14 |
| Ondansetron | 15 | $210 | $14 |
| Tramadol | 21 | $139 | $7 |
| Lisinopril | 17 | $131 | $8 |
| Acyclovir | 12 | $105 | $9 |
| Hydromorphone | 12 | $101 | $8 |
| Ciprofloxacin | 12 | $51 | $4 |
| Sulfamethoxazole-Trimethoprim | 12 | $44 | $4 |
| Furosemide | 12 | $39 | $3 |
2014: 29 drugs
| Revlimid | 22 | $211,835 | $9,629 |
| Gleevec | 20 | $167,075 | $8,354 |
| Xtandi | 18 | $164,018 | $9,112 |
| Tarceva | 23 | $134,396 | $5,843 |
| Exemestane | 24 | $6,439 | $268 |
| Xarelto | 16 | $5,707 | $357 |
| Letrozole | 257 | $4,285 | $17 |
| Celebrex | 13 | $2,691 | $207 |
| Hydrocodone-Acetaminophen | 75 | $2,237 | $30 |
| Anastrozole | 93 | $1,537 | $17 |
| Oxycodone | 24 | $1,070 | $45 |
| Lorazepam | 134 | $983 | $7 |
| Morphine Sulfate Er | 12 | $945 | $79 |
| Hydroxyurea | 26 | $701 | $27 |
| Tamoxifen Citrate | 29 | $603 | $21 |
| Prochlorperazine Maleate | 51 | $447 | $9 |
| Potassium Chloride | 17 | $414 | $24 |
| Ondansetron Odt | 16 | $385 | $24 |
| Dexamethasone | 39 | $370 | $9 |
| Prednisone | 33 | $298 | $9 |
| Omeprazole | 32 | $240 | $8 |
| Escitalopram | 12 | $229 | $19 |
| Tamsulosin | 16 | $213 | $13 |
| Zolpidem | 26 | $209 | $8 |
| Minocycline | 11 | $188 | $17 |
| Tramadol | 14 | $143 | $10 |
| Ondansetron | 11 | $122 | $11 |
| Lisinopril | 11 | $90 | $8 |
| Furosemide | 18 | $67 | $4 |
2013: 34 drugs
| Tarceva | 33 | $178,412 | $5,406 |
| Revlimid | 16 | $151,672 | $9,480 |
| Xtandi | 12 | $137,865 | $11,489 |
| Gleevec | 20 | $134,251 | $6,713 |
| Xalkori | 12 | $132,498 | $11,041 |
| Zytiga | 12 | $79,345 | $6,612 |
| Enoxaparin | 11 | $15,157 | $1,378 |
| Exemestane | 45 | $9,748 | $217 |
| Letrozole | 192 | $4,556 | $24 |
| Celebrex | 11 | $4,226 | $384 |
| Anastrozole | 80 | $2,661 | $33 |
| Hydrocodone-Acetaminophen | 105 | $2,256 | $21 |
| Fentanyl | 12 | $1,923 | $160 |
| Bicalutamide | 16 | $1,161 | $73 |
| Oxycodone | 25 | $1,080 | $43 |
| Tamoxifen Citrate | 38 | $741 | $20 |
| Megestrol Acetate | 15 | $727 | $48 |
| Lorazepam | 104 | $707 | $7 |
| Morphine Sulfate Er | 12 | $524 | $44 |
| Potassium Chloride | 12 | $410 | $34 |
| Omeprazole | 34 | $290 | $9 |
| Tamsulosin | 13 | $244 | $19 |
| Prochlorperazine Maleate | 31 | $223 | $7 |
| Ondansetron | 12 | $218 | $18 |
| Benazepril | 16 | $213 | $13 |
| Ropinirole | 11 | $206 | $19 |
| Zolpidem | 27 | $192 | $7 |
| Warfarin | 18 | $174 | $10 |
| Alendronate | 12 | $125 | $10 |
| Dexamethasone | 11 | $113 | $10 |
| Temazepam | 14 | $111 | $8 |
| Tramadol | 11 | $87 | $8 |
| Furosemide | 15 | $83 | $6 |
| Prednisone | 16 | $79 | $5 |
Money from drug and device companies
$778 in 2025
| 2025 | 15 | 30 | None | $778 |
| 2024 | 15 | 22 | None | $604 |
| 2023 | 10 | 20 | None | $531 |
| 2022 | 22 | 50 | $937 | $1,898 |
| 2021 | 19 | 66 | None | $1,859 |
| 2020 | 21 | 41 | None | $1,111 |
| 2019 | 27 | 83 | None | $1,386 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $161 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $89 | 4 payments
|
| Regeneron Pharmaceuticals | Lynozyfic | $80 | 2 payments
|
| Gilead Sciences | Trodelvy | $67 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $62 | 3 payments
|
| EMD Serono | None | $56 | 1 payment
|
See all 30 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-30 | Lynparza | $25 |
| Genentech USA | Meals · 2025-12-16 | Itovebi | $21 |
| Daiichi Sankyo | Meals · 2025-12-09 | Datroway | $19 |
| Daiichi Sankyo | Meals · 2025-12-05 | Enhertu | $29 |
| Daiichi Sankyo | Meals · 2025-11-18 | Enhertu | $28 |
| Regeneron Pharmaceuticals | Meals · 2025-11-11 | Lynozyfic | $38 |
| Gilead Sciences | Meals · 2025-11-11 | Trodelvy | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-04 | Iclusig | $19 |
| Daiichi Sankyo | Meals · 2025-10-22 | Enhertu | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | Enhertu | $24 |
| Merck Sharp & Dohme | Meals · 2025-10-17 | Keytruda | $33 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-14 | Nubeqa | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-26 | Enhertu | $21 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-12 | Onivyde | $32 |
| Regeneron Pharmaceuticals | Meals · 2025-08-31 | Lynozyfic | $41 |
| Daiichi Sankyo | Meals · 2025-08-21 | Datroway | $26 |
| Daiichi Sankyo | Meals · 2025-08-19 | Datroway | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-31 | None | $25 |
| Gilead Sciences | Meals · 2025-07-22 | Trodelvy | $22 |
| Daiichi Sankyo | Meals · 2025-06-18 | Enhertu | $7 |
| EMD Serono | Education · 2025-06-13 | None | $56 |
| Rigel Pharmaceuticals | Meals · 2025-05-08 | Tavalisse | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-24 | Iclusig | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-15 | Enhertu | $19 |
| Genentech USA | Meals · 2025-04-08 | Tecentriq Hybreza | $33 |
| Stemline Therapeutics | Meals · 2025-04-07 | Orserdu | $20 |
| Array Biopharma | Meals · 2025-03-25 | Braftovi | $23 |
| Abbvie | Meals · 2025-03-21 | None | $28 |
| Gilead Sciences | Meals · 2025-02-27 | Trodelvy | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-04 | Ninlaro | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $604
| Pfizer | Ibrance | $85 | 4 payments
|
| Lilly USA | Jaypirca | $64 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $64 | 2 payments
|
| Abbvie | Imbruvica | $62 | 2 payments
|
| Stemline Therapeutics | Orserdu | $43 | 1 payment
|
| Janssen Biotech | Darzalex | $36 | 1 payment
|
| Array Biopharma | Lorbrena | $35 | 1 payment
|
| Daiichi Sankyo | Enhertu | $34 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $32 | 1 payment
|
| Novartis Pharmaceuticals | Scemblix | $30 | 1 payment
|
| Celgene | Reblozyl | $30 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $28 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $23 | 1 payment
|
| Genmab U.S. | Epkinly | $23 | 1 payment
|
| Gilead Sciences | None | $14 | 1 payment
|
2023: $531
| Progenics Pharmaceuticals | Pylarify | $150 | 1 payment
|
| Pfizer | Ibrance | $114 | 6 payments
|
| GlaxoSmithKline | Jemperli | $53 | 2 payments
|
| Novartis Pharmaceuticals | Piqray | $41 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $39 | 2 payments
|
| Mirati Therapeutics | Krazati | $37 | 2 payments
|
| GE HealthCare | None | $26 | 2 payments
|
| BeiGene USA | Brukinsa | $25 | 1 payment
|
| Seagen | Padcev | $25 | 1 payment
|
| Celgene | Pomalyst | $20 | 1 payment
|
2022: $1,898
| EMD Serono | None | $937 | 7 payments
|
| Celgene | Pomalyst | $118 | 6 payments
|
| Taiho Oncology | Inqovi | $93 | 1 payment
|
| GlaxoSmithKline | Zejula | $91 | 5 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $88 | 3 payments
|
| Novartis Pharmaceuticals | Adakveo | $82 | 4 payments
|
| Janssen Biotech | Erleada | $78 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $53 | 2 payments
|
| Seagen | Padcev | $45 | 2 payments
|
| Gilead Sciences | Trodelvy | $39 | 2 payments
|
| Astellas Pharma US | Xtandi | $37 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $30 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $23 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $23 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $23 | 1 payment
|
| Genentech USA | Venclexta | $22 | 1 payment
|
| ADC Therapeutics America | None | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $21 | 1 payment
|
| TerSera Therapeutics | Xermelo | $18 | 1 payment
|
| Kite Pharma | None | $16 | 1 payment
|
| Kyowa Kirin | Poteligeo | $15 | 1 payment
|
2021: $1,859
| EMD Serono | None | $644 | 5 payments
|
| GlaxoSmithKline | Zejula | $261 | 11 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $190 | 10 payments
|
| Novartis Pharmaceuticals | Tasigna | $122 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $90 | 4 payments
|
| Seagen | Tukysa | $85 | 3 payments
|
| Pfizer | Ibrance | $68 | 5 payments
|
| Janssen Biotech | Erleada | $66 | 4 payments
|
| Eisai | Lenvima | $62 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $43 | 2 payments
|
| Amgen | Lumakras | $41 | 2 payments
|
| Celgene | Pomalyst | $37 | 2 payments
|
| Gilead Sciences | Trodelvy | $37 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $24 | 1 payment
|
| BeiGene USA | Brukinsa | $20 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $18 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $18 | 1 payment
|
| Astellas Pharma US | Xtandi | $17 | 1 payment
|
| Taiho Oncology | Lonsurf | $15 | 1 payment
|
2020: $1,111
| Pfizer | Lorbrena | $454 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $127 | 8 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $88 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $69 | 4 payments
|
| Seagen | Padcev | $49 | 3 payments
|
| Amgen | Kyprolis | $39 | 2 payments
|
| Agios Pharmaceuticals | Tibsovo | $38 | 2 payments
|
| Janssen Biotech | Darzalex | $25 | 2 payments
|
| Genentech USA | Kadcyla | $20 | 1 payment
|
| Exelixis | Cabometyx | $19 | 1 payment
|
| Clovis Oncology | Rubraca | $19 | 1 payment
|
| Taiho Oncology | None | $19 | 1 payment
|
| Celgene | Reblozyl | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $18 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $17 | 1 payment
|
| Eisai | Lenvima | $17 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $17 | 1 payment
|
| Daiichi Sankyo | Enhertu | $16 | 1 payment
|
| Genzyme | Jevtana | $16 | 1 payment
|
| GlaxoSmithKline | Zejula | $14 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $11 | 1 payment
|
2019: $1,386
| E.R. Squibb & Sons L.L.C. | Empliciti | $178 | 14 payments
|
| Pfizer | Xtandi | $148 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $112 | 8 payments
|
| Genentech USA | Perjeta | $107 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $103 | 6 payments
|
| Celgene | Revlimid | $66 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $63 | 3 payments
|
| Clovis Oncology | Rubraca | $59 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $56 | 3 payments
|
| Janssen Biotech | Imbruvica | $44 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $43 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $43 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $41 | 2 payments
|
| Genzyme | Elitek | $38 | 2 payments
|
| Daiichi Sankyo | Injectafer | $28 | 1 payment
|
| Lilly USA | Verzenio | $28 | 2 payments
|
| Exelixis | Cabometyx | $27 | 1 payment
|
| AbbVie | Venclexta | $25 | 1 payment
|
| Array BioPharma | Braftovi | $24 | 1 payment
|
| Seattle Genetics | None | $23 | 1 payment
|
| Lexicon Pharmaceuticals | Xermelo | $22 | 1 payment
|
| Astellas Pharma US | Xospata | $22 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $20 | 1 payment
|
| Medtronic USA | Kyphon Balloon Kyphoplasty | $19 | 1 payment
|
| Gilead Sciences | None | $17 | 1 payment
|
| Eisai | Lenvima | $15 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genmab U.S., Inc. · Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/Or Metastatic Solid Tumors · 2025 | Their institution | $1,196,131 |
| AstraZeneca AB · A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study To Assess Efficacy and Safety of Multiple Dose Levels of Azd7594 Dpi Given Once Daily for Twelve Weeks, Compared To Placebo, in Asthmatics Symptomatic on Low Dose Ics · 2019 | Their institution | $271,051 |
| Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/ Tsc2 Genes (Precision 1) · 2023 | Their institution | $170,241 |
| AstraZeneca Pharmaceuticals LP · A Phase 2, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2022 | Their institution | $153,727 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2021 | Their institution | $152,822 |
| Genmab U.S., Inc. · Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/Or Metastatic Solid Tumors · 2024 | Their institution | $148,996 |
| Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2023 | Their institution | $131,974 |
| Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2020 | Their institution | $131,369 |
| Merck Sharp & Dohme Corporation · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2021 | Their institution | $122,199 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2022 | Their institution | $118,653 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2024 | Their institution | $118,521 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024 | Their institution | $117,632 |
| AstraZeneca UK Limited · A Phase III,Open Label,Sponsor Blind,Randomized Study of Dato Dxd With Or Without Osimertinib Versus Platinum Based Doublet Chemotherapy for Participants With Egfr Mutated Locally Advanced Or Metastatic Non Small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment Tropion Lung15 · 2025 | Their institution | $112,570 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (Medi5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed Or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (Evolve-Meso) · 2025 | Their institution | $110,251 |
| Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 Plus Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2023 | Their institution | $102,579 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (Adriatic) · 2020 | Their institution | $100,753 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2022 | Their institution | $97,284 |
| AstraZeneca Pharmaceuticals LP · A Phase 2 Study of Tdxd in Patients With Selected Her2 Expressing Tumors · 2021 | Their institution | $93,759 |
| Seagen Inc. · An Open-Label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy With Optional Maintenance Therapy in Subjects With Her2 Expressing Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer · 2023 | Their institution | $93,302 |
| Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1tsc2 Genes Precision 1 · 2024 | Their institution | $90,302 |
| Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Loc · 2025 | Their institution | $86,422 |
| Merck Sharp & Dohme LLC · A Phase 1,2 Dose Escalation,Expansion Study of Ngm707 As Monotherapy and in Combination With Pembrolizumab in Advanced Or Metastatic Solid Tumor Malignancies · 2023 | Their institution | $85,200 |
| Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 + Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2025 | Their institution | $84,792 |
| AstraZeneca Pharmaceuticals LP · A Phase II Open-Label Multi-Centre Study To Evaluate Safety Tolerability Efficacy Pk and Immunogenicity of Azd0901 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 182 · 2024 | Their institution | $78,803 |
| Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer · 2025 | Their institution | $77,620 |
| Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025 | Their institution | $72,520 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2022 | Their institution | $70,541 |
| Exelixis Inc. · A Randomized Open-Label Phase 3 Study of Xl092 + Atezolizumab Vs Regorafenib in Subjects With Metastatic Colorectal Cancer · 2024 | Their institution | $70,361 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2022 | Their institution | $68,600 |
| AstraZeneca Pharmaceuticals LP · A Phase II Open-Label Multi-Centre Study To Evaluate Safety Tolerability Efficacy Pk and Immunogenicity of Azd0901 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 182 · 2025 | Their institution | $65,862 |
| Merck Sharp & Dohme Corporation · An Open-Label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-Line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Tnbc Keylynk 009 · 2020 | Their institution | $63,546 |
| Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2023 | Their institution | $60,246 |
| AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2019 | Their institution | $59,161 |
| EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2020 | Their institution | $58,342 |
| AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2024 | Their institution | $57,114 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2022 | Their institution | $56,814 |
| AstraZeneca Pharmaceuticals LP · A Phase II Multicenter Open Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan Tdxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2021 | Their institution | $56,398 |
| Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Loc · 2024 | Their institution | $54,690 |
| EMD Serono, Inc. · A Phase II, Open-Label, Single-Arm Study Ofberzosertib (M6620) in Combination Withtopotecan in Participants With Relapsedplatinum-Resistant Small-Cell Lung Cancer · 2021 | Their institution | $51,255 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2023 | Their institution | $49,774 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2023 | Their institution | $47,595 |
| AstraZeneca Pharmaceuticals LP · Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy · 2021 | Their institution | $47,246 |
| Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2020 | Their institution | $45,726 |
| Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2022 | Their institution | $44,700 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2021 | Their institution | $43,853 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2020 | Their institution | $43,715 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2021 | Their institution | $43,361 |
| Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2021 | Their institution | $42,899 |
| Merck Sharp & Dohme Corporation · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2020 | Their institution | $42,176 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2023 | Their institution | $42,025 |
| Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2021 | Their institution | $41,819 |
| AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2025 | Their institution | $41,785 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2023 | Their institution | $41,430 |
| AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2025 | Their institution | $40,205 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2025 | Their institution | $39,966 |
| AstraZeneca UK Limited · An Open Label,Single Arm, Phase Two,Multinational,Multicentre Study To Assess the Efficacy and Safety of Five Years of Osimertinib in Participants With Epidermal Growth Factor Receptor Mutation Positive Stage Two 3b Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy Target · 2023 | Their institution | $39,755 |
| AstraZeneca Pharmaceuticals LP · A Phase 2, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd for the Treatment of Unresectable and Or Metastatic Solid Tumors Harboring Her2 Activating Mutations Regardless of Tumor Histology · 2023 | Their institution | $39,735 |
| Merck Sharp & Dohme LLC · A Phase 3 Study of Pembrolizumab Mk-3475 in Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib Vs Concurrent Chemoradiation Therapy Followed By Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Nsclc · 2022 | Their institution | $39,084 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2021 | Their institution | $38,619 |
| AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2023 | Their institution | $37,581 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2019 | Their institution | $36,999 |
| PFIZER INC. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated Locallyadvanced Unresectable Or Metastatic Solid Tumors That Express Her2 · 2024 | Their institution | $34,599 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2024 | Their institution | $33,417 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (Medi5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed Or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (Evolve-Meso) · 2024 | Their institution | $32,665 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (La Hnscc) · 2019 | Their institution | $32,492 |
| Seagen Inc. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable Or Metastatic Solid Tumors That Express Her2. · 2023 | Their institution | $31,652 |
| AstraZeneca Pharmaceuticals LP · Phase 2 Multicenter Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-Dxd Ds-8201a) for the Treatment of Selected Her2 Expressing Tumours (Destiny-Pantumor02) · 2025 | Their institution | $31,126 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2020 | Their institution | $30,776 |
| Astellas Pharma Global Development · An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma · 2020 | Their institution | $30,728 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-Dxd, Ds-8201a for the Treatment of Selected Her2-Expressing Tumors Destiny Pantumor02 · 2024 | Their institution | $30,707 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2020 | Their institution | $30,622 |
| Seagen Inc. · A Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (Asg-22ce) in Combination With Pembrolizumab and/Or Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2023 | Their institution | $30,220 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Double Blind Multicenter Global Study of Rilvegostomig Or Pembrolizumab in Combination With Platinum Based Chemotherapy for the First Line Treatment of Patients With Metastatic Non Squamous Non Small Cell Lung Cancer Whose Tumors Express Pdl1 Artemide Lung03 · 2025 | Their institution | $28,625 |
| Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2023 | Their institution | $28,200 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2021 | Their institution | $27,403 |
| PFIZER INC. · A Phase 2b3 Randomized Doubleblind Study To Investigate the Efficacy Safety and Tolerability of Ponsegromab Pf06946860 Compared With Placebo Both With Background Firstline Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma · 2025 | Their institution | $27,388 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2022 | Their institution | $27,250 |
| Daiichi Sankyo Inc. · Enhertu · 2025 | Their institution | $27,211 |
| AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2020 | Their institution | $27,138 |
| AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2019 | Their institution | $27,032 |
| Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2025 | Their institution | $26,941 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2020 | Their institution | $26,220 |
| EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2022 | Their institution | $26,159 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2023 | Their institution | $26,059 |
| AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2019 | Their institution | $25,815 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2023 | Their institution | $25,635 |
| Merck Sharp & Dohme LLC · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2022 | Their institution | $25,496 |
| BeiGene, Ltd. · A Randomized, Controlled, Open-Label, Global Phase 3 Study Comparing the Efficacy of the Anti-Pd-1 Antibody Tislelizumab (Bgb-A317) Versus Chemotherapy As Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car · 2023 | Their institution | $25,450 |
| AstraZeneca Pharmaceuticals LP · A Phase Ib Multicenter, Open-Label Dose-Escalation Study To Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-Dxd) and Durvalumab in Combination With Cisplatin, Carboplatin Or Pemetrexed in First-Line Treatment of Patients With Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) and Human Epidermal Growth Factor Receptor 2 Overexpression (Her2 Positive) (Destiny-Lung03). · 2022 | Their institution | $25,400 |
| Mirati Therapeutics, Inc. · A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023 | Their institution | $24,855 |
| Incyte Corporation · A Study of Incmga00012 in Participants With Selected Solid Tumors Pod1um-203 · 2019 | Their institution | $24,769 |
| AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2025 | Their institution | $24,618 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2019 | Their institution | $24,065 |
| ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and Or Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2023 | Their institution | $23,835 |
| Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2025 | Their institution | $23,545 |
| Seagen Inc. · An Open-Label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzamab and Mfolfox6 Given With Or Without Either Cetuximab Or Bevacizumab As First-Line Treatment for Subjects With Her2+ Metastatic Colorectal Cancer. · 2022 | Their institution | $22,870 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study To Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-Based Chemotherapy in Completely Resected Stage II-III Nsclc Mermaid 1 · 2020 | Their institution | $22,399 |
| Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Mrtx849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023 | Their institution | $22,390 |
| Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2024 | Their institution | $22,279 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2025 | Their institution | $22,108 |
| AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2023 | Their institution | $21,975 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2019 | Their institution | $21,847 |
| Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2021 | Their institution | $21,489 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2025 | Their institution | $21,478 |
| Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2024 | Their institution | $20,780 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2019 | Their institution | $20,618 |
| Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2019 | Their institution | $20,515 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2020 | Their institution | $20,334 |
| AbbVie, Inc. · 2019 | Their institution | $20,191 |
| PFIZER INC. · An Openlabel Randomized Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy With Optional Maintenance Therapy in Subjects With Her2 Expressing Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer · 2024 | Their institution | $20,009 |
| Seattle Genetics, Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin Lv for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2019 | Their institution | $19,468 |
| Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019 | Their institution | $19,284 |
| Seagen Inc. · An Open-Label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzamab and Mfolfox6 Given With Or Without Either Cetuximab Or Bevacizumab As First-Line Treatment for Subjects With Her2+ Metastatic Colorectal Cancer. · 2023 | Their institution | $19,085 |
| Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/?Tsc2 Genes (Precision 1) · 2025 | Their institution | $19,019 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2022 | Their institution | $18,906 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025 | Their institution | $18,524 |
| Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2021 | Their institution | $18,426 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2021 | Their institution | $18,255 |
| EMD Serono, Inc. · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2021 | Their institution | $18,213 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2024 | Their institution | $17,517 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2025 | Their institution | $17,066 |
| Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2022 | Their institution | $16,781 |
| AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2022 | Their institution | $15,912 |
| Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $15,760 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2021 | Their institution | $15,554 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2024 | Their institution | $15,462 |
| Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2020 | Their institution | $15,453 |
| Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2020 | Their institution | $15,394 |
| Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2024 | Their institution | $15,267 |
| AstraZeneca Pharmaceuticals LP · A Phase Ib Multicenter, Open-Label Dose-Escalation Study To Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-Dxd) and Durvalumab in Combination With Cisplatin, Carboplatin Or Pemetrexed in First-Line Treatment of Patients With Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) and Human Epidermal Growth Factor Receptor 2 Overexpression (Her2 Positive) (Destiny-Lung03). · 2023 | Their institution | $15,106 |
| AbbVie Inc. · Venclexta · 2020 | Their institution | $15,100 |
| AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2020 | Their institution | $14,659 |
| Merck Sharp & Dohme LLC · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2024 | Their institution | $14,507 |
| ABBVIE INC. · A Phase 1, Multicenter, Open-Label Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and/Or Chemotherapy in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021 | Their institution | $14,500 |
| Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiationand As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advancedhead and Neck Squamous Cell Carcinoma · 2019 | Their institution | $14,421 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2: A Phase Iia/Iib, Open-Label, Single-Arm, Multi-Centre Trial of Bi 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, Mdm2 Amplified, Tp53 Wild-Type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Or Other Selected Solid Tumours · 2025 | Their institution | $14,371 |
| Merck Sharp & Dohme LLC · A Phase 1,2 Dose Escalation,Expansion Study of Ngm707 As Monotherapy and in Combination With Pembrolizumab in Advanced Or Metastatic Solid Tumor Malignancies · 2024 | Their institution | $14,200 |
| AstraZeneca Pharmaceuticals LP · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2019 | Their institution | $13,892 |
| AstraZeneca Pharmaceuticals LP · A Phase Two Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrmpplus and Metplus,Locally Advanced Or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2022 | Their institution | $13,879 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2023 | Their institution | $13,763 |
| AstraZeneca Pharmaceuticals LP · This Is A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre, International Study Assessing the Efficacy and Safety of Durvalumab Medi4736 and Domvanalimab Ab154 Compared With Durvalumab Plus Placebo in Adults With Locally Advanced Stage III · 2024 | Their institution | $13,343 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage Iib Or Iiia Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2019 | Their institution | $13,273 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2021 | Their institution | $12,428 |
| AstraZeneca Pharmaceuticals LP · A Phase I/Iia Multi-Center, Open-Label Master Protocol To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of Azd8205 in Participants With Advanced Or Metastatic Solid Malignancies · 2024 | Their institution | $11,760 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advancedmetastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations Fight-207 · 2019 | Their institution | $11,536 |
| Boehringer Ingelheim International GmbH · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2020 | Their institution | $11,025 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2021 | Their institution | $10,806 |
| Incyte Corporation · A Phase 1, Open-Label Study To Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment · 2020 | Their institution | $10,795 |
| AstraZeneca UK Limited · A Global Study To Assess the Effects of Medi4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer · 2021 | Their institution | $10,439 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2022 | Their institution | $10,300 |
| Genmab U.S., Inc. · A Phase 2, Multicenter, Randomized, Open-Label Trial of Gen1046 As Monotherapy and in Combination With Anti-Cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With An Immune Checkpoint Inhibitor · 2025 | Their institution | $9,852 |
| AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2020 | Their institution | $9,612 |
| Merck Sharp & Dohme Corporation · An Open-Label, Randomized Phase 3 Study of Mk-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior Pd-1,L1 and Vegf-Targeted Therapies · 2019 | Their institution | $9,480 |
| Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2022 | Their institution | $9,096 |
| Halozyme Inc · A Phase 1b Open-Label Study of Pegylated Recombinant Human Hyaluronidase (Pegph20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors · 2019 | Their institution | $8,747 |
| Astellas Pharma Global Development · A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2022 | Their institution | $8,654 |
| AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2021 | Their institution | $8,445 |
| Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2022 | Their institution | $8,250 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2020 | Their institution | $7,813 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab Or Durvalumab and Tremelimumab As Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy Adriatic · 2024 | Their institution | $7,790 |
| Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2022 | Their institution | $7,762 |
| AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2020 | Their institution | $7,594 |
| Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2025 | Their institution | $7,353 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2022 | Their institution | $7,255 |
| Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab Vs. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression · 2020 | Their institution | $7,206 |
| AbbVie Inc. · 2020 | Their institution | $7,069 |
| Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Nivolumab Vs. Nivolumab Alone As Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of Pd-L1 · 2020 | Their institution | $6,420 |
| Merck Healthcare KGaA · A Phase II Single-Arm Trial To Investigate Tepotinib in Advanced (Stage Iiib and IV) Non-Small Cell Lung Cancer With Met Exon 14 (Metex14) Skipping Alterations Or Met Amplification (Vision) · 2025 | Their institution | $6,347 |
| AstraZeneca UK Limited · An Open Label Multi Centre Safety Study of Fixed Dose Durvalumab Plus Tremelimumab Combination Therapy Or Durvalumab Monotherapy in Advanced Solid Malignancies Strong · 2019 | Their institution | $5,422 |
| AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2021 | Their institution | $5,419 |
| Merck Sharp & Dohme LLC · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2023 | Their institution | $5,392 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2025 | Their institution | $5,340 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2023 | Their institution | $5,300 |
| ABBVIE INC. · A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (Nsclc) With High Programmed Cell Death Ligand-1 (Pd-L1) Expression · 2022 | Their institution | $5,000 |
| PFIZER INC. · A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated Locallyadvanced Unresectable Or Metastatic Solid Tumors That Express Her2 · 2025 | Their institution | $4,860 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2020 | Their institution | $4,708 |
| Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2022 | Their institution | $4,300 |
| Merck Sharp & Dohme Corporation · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2021 | Their institution | $4,232 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - Mm Study · 2022 | Their institution | $4,170 |
| Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2020 | Their institution | $4,161 |
| Halozyme Inc · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Pegylated Recombinant Human Hyaluronidase (Pegph20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit · 2019 | Their institution | $4,124 |
| Merck Sharp & Dohme Corporation · A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and As Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma · 2021 | Their institution | $3,982 |
| Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Phase 2 Basket Study To Evaluate the Safety and Efficacy of Mk-2140 As A Monotherapy and in Combination in Participants With Aggressive and Indolent B-Cell Malignancies. · 2021 | Their institution | $3,869 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2025 | Their institution | $3,800 |
| Takeda Pharmaceuticals U.S.A., Inc. · The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma Insight · 2019 | This clinician | $3,705 |
| Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab Vs. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression · 2019 | Their institution | $3,693 |
| Astellas Pharma Global Development · A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2021 | Their institution | $3,366 |
| GlaxoSmithKline, LLC. · A Randomized, Double-Blind, Adaptive, Phase II/III Study of Gsk3359609 · 2020 | Their institution | $3,100 |
| Merck Sharp & Dohme Corporation · A Phase II Clinical Trial of Single Agent Pembrolizumab Mk-3475 in Subjects With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma Hnscc Who Have Failed Platinum and Cetuximab · 2019 | Their institution | $3,050 |
| Merck Sharp & Dohme Corporation · An Open-Label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-Line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Tnbc Keylynk 009 · 2021 | Their institution | $3,025 |
| AstraZeneca Pharmaceuticals LP · A Study of Osimertinib With Or Without Chemotherapy As 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (Flaura2) · 2024 | Their institution | $2,937 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2021 | Their institution | $2,653 |
| Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety Andefficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma R,M Cscc · 2019 | Their institution | $2,600 |
| AstraZeneca Pharmaceuticals LP · A Biomarker-Directed Phase 2 Platform Study in Patients With Advanced Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (Orchard) · 2022 | Their institution | $2,580 |
| Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2024 | Their institution | $2,500 |
| AstraZeneca Pharmaceuticals LP · A Phase III Randomized Multicenter Double-Blind Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III Nsclc Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy (Mermaid-2) · 2023 | Their institution | $2,500 |
| Astellas Pharma Global Development · A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy Adt Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer Mhspc · 2019 | Their institution | $2,369 |
| ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) and Or Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $2,340 |
| ABBVIE INC. · A Study To Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Abbv-927 With Abbv-368, Budigalimab (Abbv-181) Andx2for Chemotherapy in Participants With Locally Advanced Or Metastatic Solid Tumors · 2022 | Their institution | $2,320 |
| ABBVIE INC. · A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated Nsclc Whose Tumors Have High Pd-L1 Expression · 2021 | Their institution | $2,275 |
| GlaxoSmithKline, LLC. · A Randomized, Double-Blind, Adaptive, Phase II/III Study of Gsk3359609 · 2022 | Their institution | $2,200 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2020 | Their institution | $2,174 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024 | Their institution | $2,052 |
| PFIZER INC. · An Openlabel Randomized Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced Or Metastatic Urothelial Carcinoma That Expresses Her2 Ihc 1 and Greater · 2024 | Their institution | $2,040 |
| Mirati Therapeutics, Inc. · A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With Kras G12c Mutation · 2024 | Their institution | $2,030 |
| PFIZER INC. · A Phase II Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2 Metastatic Colorectal Cancer Mountaineer · 2024 | Their institution | $2,000 |
| Novartis Pharmaceuticals Corporation · Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab Vs Placebo in Adjuvant Setting · 2022 | Their institution | $1,924 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With Egfrm+ and Met+, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib · 2021 | Their institution | $1,611 |
| AstraZeneca Pharmaceuticals LP · Study of 1st Line Therapy Study of Medi4736 With Tremelimumab Versus Soc in Non Small Cell Lung Cancer Nsclc Neptune · 2019 | Their institution | $1,528 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2023 | Their institution | $1,486 |
| AstraZeneca Pharmaceuticals LP · To Assess the Efficacy and Safety of Azd9291 Versus Placebo in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage Ib Iiia Non Small Cell Lung Carcinoma Following Complete Tumour Resection With Or Without Adjuvant Chemotherapy · 2024 | Their institution | $1,411 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2024 | Their institution | $1,350 |
| Incyte Corporation · A Study of Incmga00012 in Participants With Selected Solid Tumors (Pod1um-203) · 2020 | Their institution | $1,306 |
| Astellas Pharma Global Development · A Study of Enzalutamide Plus Androgen Deprivation Therapy (Adt) Versus Placebo Plus Adt in Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2020 | Their institution | $1,282 |
| Eli Lilly and Company · A Randomized Phase 2 Trial of Am0010 in Combination With Nivolumab Vs. Nivolumab Alone As Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of Pd-L1 · 2019 | Their institution | $1,251 |
| Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2023 | Their institution | $1,225 |
| Merck Sharp & Dohme Corporation · A Phase III Study of Pembrolizumab Vs Chemotherapy in Microsatellite Instability- High Or Mismatched Repair Deficient Colorectal Carcinoma · 2019 | Their institution | $1,100 |
| Puma Biotechnology, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib · 2019 | Their institution | $720 |
| Boehringer Ingelheim International GmbH · Ph1 Mono/Combi+Pd1 in Advanced Tumours · 2021 | Their institution | $675 |
| Merck Sharp & Dohme LLC · A Phase II Trial of Pembrolizumab Mk-3475 in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer Nsclc Keynote-799. · 2025 | Their institution | $670 |
| PUMA BIOTECHNOLOGY, INC. · A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (Hki-272) After Trastuzumab in Women With Early-Stage Her-2/Neu Overexpressed/Amplified Breast Cancer · 2020 | Their institution | $600 |
| Boehringer Ingelheim International GmbH · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024 | Their institution | $576 |
| AstraZeneca Pharmaceuticals LP · Study of 1st Line Therapy Study of Medi4736 With Tremelimumab Versus Soc in Non Small Cell Lung Cancer Nsclc Neptune · 2020 | Their institution | $538 |
| Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab Vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-Small Cell Lung Cancer Subjects Whose Tumors Are Pd-L1 Positive Tps 50 · 2019 | Their institution | $500 |
| AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2022 | Their institution | $457 |
| Merck Sharp & Dohme Corporation · A Phase III, Multicenter, Randomized Study To Evaluate Mk 1308a Co-Formulated Mk 1308,Mk 3475 Versus Chemotherapy As Adjuvant Therapy Following Surgery in Participants With Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr High Risk Stage III Colorectal Cancer Mk 1308a-007 Aim-High · 2021 | Their institution | $344 |
| PFIZER INC. · A Doseescalation and Doseexpansion Study of Enfortumab Vedotin Asg22ce in Combination With Pembrolizumab Andor Chemotherapy for Treatment of Patients With Locally Advanced Or Metastatic Urothelial Cancer · 2024 | Their institution | $300 |
| E.R. Squibb & Sons, L.L.C. · Trident-1 - Ros1+ Nsclc - Primary Study - A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Tpx-0005 in Patients With Advanced Solid Tumors Harboring Alk, Ros1, Or Ntrk1-3 · 2023 | Their institution | $290 |
| Seagen Inc. · Open-Label Phase 2 Study of Ladiratuzumab Vedotin (Lv) for Unresectable Locally Advanced Or Metastatic Solid Tumors · 2023 | Their institution | $245 |
| Seagen Inc. · Screening Protocol To Detect Her2 Alterations Required for Enrollment on Clinical Research Protocols of Tucatinib · 2023 | Their institution | $100 |
| AstraZeneca UK Limited · Azd9291 Versus Gefitinib Or Erlotinib in Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2021 | Their institution | $57 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic Or Surgically Unresectable Solid Tumor Malignancies Harboring Activating Fgfr Mutations Or Translocations (Fight-207) · 2022 | Their institution | $18 |
Professional record
- NPI
- 1518055573
- Licence
- CA A49481California A49481: Current · expires 2027-11-30
- Trained
- Duke University School of Medicine, 1988 · 38 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A494810
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Federal specialty code 207RH0000X (207RH0000X); Medical oncology (207RX0202X)
- Mailing address
- 3555 Round Barn Cir, Santa Rosa, CA, 95403
- NPI first listed
- 2006-10-11
- NPI last updated
- 2021-10-14
- NPI record certified
- 2021-10-14
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.